摘要
目的探讨血清人附睾分泌蛋白4(HE4)联合糖链多肽抗原125(CA125)对卵巢癌患者的早期诊断和预后随诊的价值。方法将天津市中心妇产科医院2011年11月至2012年5月收治的68例诊断为卵巢癌的患者纳入卵巢癌组,将同期收入院的72例诊断为妇科良性肿块的患者(其中有卵巢巧克力囊肿37例,卵巢良性肿瘤27例,盆腔脓肿8例)纳入良性肿块组,因体检来院的健康妇女40例纳入对照组。采用酶联免疫吸附法(ELISA)和电化学发光法测定3组妇女的血HE4和CA125水平,结合患者的月经情况进行统计和分析。结果 (1)未绝经组和已绝经组中,卵巢癌患者的HE4和CA125水平均高于良性肿块组和健康对照组,差异均有统计学意义(P<0.05,P<0.01);未绝经组的HE4水平检测对卵巢癌的预测特异度和阳性预测值分别为96.6%和92.8%,已绝经组为90.7%和93.4%,两组均明显高于CA125的检测特异度和阳性预测值(未绝经组为69.8%和59.1%,已绝经组为65.6%和62.7%)。(2)利用卵巢癌风险模型(ROMA模型)对卵巢癌组进行评估,ROMA模型的灵敏度为87.3%,特异度为77.8%;(3)卵巢癌患者术后1个月复查HE4和CA125水平,较术前明显下降,差异有统计学意义(P<0.05)。结论 HE4与CA125早期诊断卵巢癌的灵敏度相当;HE4的特异性高于CA125,HE4对于卵巢癌的预后评估具有一定价值;HE4联合CA125对卵巢癌患者的早期诊断和预后的评估有重要的临床价值,值得在临床推广应用。
Objective To explore the roles of human sapiens epididymis specific protein 4 （HE4） with carbohydrate antigen 125 （CA125） in early diagnosis and prognosis of human ovarian cancer. Methods The subjects were divided into cancer group （68 cases with ovarian cancer）, benign tumor group （72 cases with gynecological benign tumors） and control group （40 healthy women） from November of 2011 to May of 2012. The levels of HE4 and CA125 in 3 groups were measured by ELISA and electrochemical luminescence methods. Results The level of HE4 in the cancer group was significantly higher than those in the benign tumor group and control group among the premenopausal females and menopausal females （P〈0.01）. The specificity and positive predictive values of HE4 for ovarian cancer were 96.6% and 92.8% for premenopausal females, 90.7% and 93.4% for menopausal females, which were significantly higher than those （69.8% or 59.1%, 65.6% or 62,7%） of CA125. The sensitivity and specificity of ROMA model were 87.3% and 77.8%. The levels of HE4 and CA125 in cancer group after treatment were significantly lower than those before treatment （P〈0.05）. Conclusion HE4 and CA125 have the similar sensitivity in early diagnosis of ovarian cancer. But the specificity of HE4 is higher than that of CA125. The combination of HE4 with CA125 has important clinical significance in early diagnosis and prognosis of human ovarian cancer.
出处
《中国慢性病预防与控制》
CAS
2013年第3期312-314,共3页
Chinese Journal of Prevention and Control of Chronic Diseases
关键词
卵巢癌
人附睾分泌蛋白4
糖链多肽抗原125
早期诊断
Ovarian cancer
Human sapiens epididymis specific protein 4
Carbohydrate antigen 125
Early diagnosis
